Introduction {#sec1}
============

Mesenchymal stromal cells (MSCs) are multipotent adult progenitor cells capable of differentiating into various mesenchymal tissues, most prominently bone, cartilage, and adipose. They were first isolated in 1974 from the bone marrow by Friedenstein and colleagues ([@bib51]). Since then, MSCs have been isolated from a variety of other tissues, including adipose ([@bib175]), perivasculature ([@bib36]), dental pulp ([@bib59]), muscle, dermis ([@bib166]), and fetal tissue ([@bib20], [@bib67]), including the Wharton jelly of umbilical cords ([@bib155]).

The International Society for Cellular Therapy (ISCT) has laid down several defining criteria for the identification of MSCs ([@bib41]): (1) they must be plastic adherent in standard culture conditions, (2) express the surface markers CD105, CD90, and CD73; (3) not express other lineage markers CD45 (panleukocyte), CD34 (hematopoietic and endothelial), CD14/CD11b (monocytic), CD79a/CD19 (B cell), or human leukocyte antigen (HLA) class II; and (4) show the classical trilineage differentiation into osteoblasts, adipocytes, and chondroblasts. Several nonclassical fates have also been demonstrated, including myoblastic ([@bib36]), hepatocytic ([@bib137]), and neural ([@bib5]), although the neural fate remains controversial. Although MSCs derived from any tissue must meet these minimal criteria, those isolated from different tissues often exhibit considerable differences in their transcriptomic profiles ([@bib70], [@bib77], [@bib141]). Of note, MSCs are not a pure population of stem cells; the ISCT criteria actually describe MSCs as a heterogeneous, nonclonal mix of multipotent stem cells, committed progenitors, and differentiated cells ([@bib139]). This fact prompted a change in nomenclature from "mesenchymal stem cell" to "mesenchymal stromal cell" to better reflect their cellular heterogeneity, although the terms are still used interchangeably.

Despite these complications surrounding their identity and isolation, there has been much interest revolving around MSCs for their therapeutic potential, especially in regenerative medicine. When tissues are damaged, MSCs are naturally released into circulation, migrate to the site of injury, and secrete molecules to create a microenvironment that promotes regeneration ([@bib23], [@bib22]). Thus the idea behind their therapeutic potential is that allogenically transplanted MSCs can home damaged tissue and act as a "drug store" to aid in recovery or serve as an effector for tissue regeneration ([@bib22]). Upon reaching the target tissue, MSCs secrete a variety of factors with powerful immune-modulating, angiogenic, and anti-apoptotic effects ([@bib90], [@bib136], [@bib13]). Accordingly, MSCs have been investigated for a wide breadth of clinical applications, such as immune modulation in inflammatory and autoimmune diseases, tissue protection following injury, and regenerative medicine ([@bib50]). However, a major hurdle still lies in getting MSCs to go where they are needed---that is, optimizing MSC homing efficiency. This review discusses the molecular details of the homing process and the various strategies that have been explored for optimizing it.

MSC Homing Mechanisms {#sec2}
=====================

One of the key benefits of MSC-based therapies is their ability to preferentially home damaged tissues. It is worth elaborating on what exactly we mean by homing, as the term is often used vaguely in the literature. Following the recommendations of previous reviews, we take homing to encompass both non-systemic and systemic homing ([@bib109]). In non-systemic homing, MSCs are transplanted locally at the target tissue and are then guided to the site of injury via a chemokine gradient. In systemic homing, MSCs are administered or endogenously recruited into the bloodstream and then must undergo a multistep process to exit circulation and migrate to the injury site. The process of systemic homing can be split into five steps: (1) tethering and rolling, (2) activation, (3) arrest, (4) transmigration or diapedesis, and (5) migration ([@bib122]) ([Figure 1](#fig1){ref-type="fig"}).Figure 1Mesenchymal Stromal Cell Homing MechanismsOverview of the molecular mechanisms facilitating each step of mesenchymal stromal cell (MSC) homing.

The initial *tethering* is facilitated by selectins expressed by endothelial cells. MSCs express CD44, which catches onto the selectins and causes the cell to begin rolling along the vasculature wall ([@bib123]). The exact selectin used by MSCs is still an active area of investigation, especially because they express neither the hematopoietic cell E- and L-selectin ligand (HCELL) nor the P-selectin glycoprotein ligand-1 (PSGL-1) ([@bib123]). To model the tethering process, Rüster et al. constructed a parallel plate flow chamber seeded with endothelial cells ([@bib120]). They demonstrated that anti-P-selectin antibodies suppress MSC binding to endothelial cells, whereas immobilized P-selectin is sufficient to induce MSC *rolling*. However, as MSCs do not express PSGL-1, they must use a different ligand to interact with P-selectin. One study has identified galectin-1 as one such candidate ([@bib142]). Another study has identified CD24 as a potential P-selectin ligand in adipose tissue-derived stromal cells, which resemble MSCs ([@bib7]).

The second step, *activation*, is facilitated by G protein-coupled chemokine receptors, generally in response to inflammatory signals. Indeed, mice subjected to total body or local irradiation have higher levels of MSC engraftment owing to the resulting inflammation response ([@bib49]). The expression of stromal cell-derived factor (SDF)-1 on endothelial cells is considered critical for this step ([@bib89]). SDF-1 is the ligand to the chemokine receptor CXCR4, which is thought to be expressed by MSCs ([@bib162], [@bib54], [@bib63]). Indeed, overexpression of CXCR4 on MSCs increases homing to the bone marrow ([@bib12]). However, some groups report that MSCs do not express CXCR4 ([@bib152]), suggesting that other receptors are also involved. Indeed, it has been shown that MSCs also express CXCR7, which similarly binds SDF-1 to facilitate homing to various tissues ([@bib94], [@bib157], [@bib133]). Other chemokines and receptors are known to play a role as well. For example, transgenic mice expressing the inflammation marker MCP-1 on the myocardium were able to recruit MSCs expressing the corresponding receptor CCR2, due to the direct interaction between the ligand and receptor ([@bib10]). In a similar study, MCP-3 expression in the myocardium greatly increased MSC engraftment as well ([@bib129]). MSCs express a variety of other receptors, including CCR1, CCR4, CCR7, CCR9, CCR10, CXCR5, and CXCR6 ([@bib63], [@bib152]), although their roles remain to be elucidated in detail. Regardless of the specific receptor-ligand interaction, the role of the activation step is to increase the affinity of integrins by inducing conformational changes in their extracellular domains; these integrins are essential for cell arrest ([@bib97], [@bib34]). For example, SDF-1 stimulation recruits the signaling molecules talin and kindlin to the cytoplasmic domain of VLA-4, causing the latter to shift to a high-affinity conformation ([@bib144]). The expression profile of these receptors likely plays a large role in determining the tissues to which MSCs will migrate.

The third step, *arrest*, is facilitated by integrins. MSCs express VLA-4 (integrin α4β1), which become activated in response to chemokines like SDF-1. Following activation, the VLA-4 integrin binds to VCAM-1 on endothelial cells ([@bib132], [@bib120], [@bib140]). Indeed, neutralizing antibodies against β1-integrin inhibit MSC homing to ischemic myocardium, although the same was not true for antibodies blocking α4-integrin ([@bib68]). Overexpression of α4-integrin increases MSC homing to the bone marrow ([@bib88]). Interestingly, the MSCs themselves also express integrin ligands including vascular cell adhesion molecule (VCAM)-1 and intercellular cell adhesion molecule (ICAM)-1 ([@bib87], [@bib86]), although their importance has not been fully evaluated.

In the next step, *transmigration* or *diapedesis*, MSCs must transcellularly travel through the endothelial cell layer and basement membrane. To accomplish this, MSCs secrete matrix metalloproteinases (MMPs) to break down the endothelial basement membrane ([@bib140]). MMP maturation and activity are regulated by various other proteins, most prominently the tissue inhibitors of metalloproteinases (TIMPs). The expression of these remodeling enzymes is induced by inflammatory cytokines, which serve as a signal for migration into damaged tissue ([@bib118]). Becker et al. showed that knockdown of MMP2 resulted in significantly decreased migration *in vitro*, as did the exogenous addition of TIMP3 to the culture media ([@bib38]). Ries et al. similarly demonstrated that knockdown of MMP2, MT1-MMP, or TIMP2 in MSCs reduces invasion, whereas knockdown of TIMP1 increases it ([@bib118]). Although it may seem strange that TIMP2 facilitates transmigration, it actually plays a role in the maturation of MMP2 from its proenzyme form to its active form ([@bib159]). There are likely more molecular interactions involved in MSC transmigration, although they are as of yet poorly understood. Leukocyte transmigration, for example, requires homophilic interactions between platelet endothelial cell adhesion molecule expressed on both the leukocyte and endothelium as well as between CD99 ([@bib106]). An equivalent process in MSCs, however, has not yet been described.

Finally, the MSC must *migrate* through the interstitium to the site of injury. This step is guided by chemotactic signals released in response to tissue damage. MSCs migrate toward various signals, including the growth factors platelet-derived growth factor-AB and insulin-like growth factor (IGF)-1, and to a lesser extent, the chemokines RANTES, MDC, and SDF-1 ([@bib115]). Preincubating the MSCs with tumor necrosis factor (TNF)-α increases their migration toward chemokines by upregulating their receptors CCR2, CCR3, and CCR4. The inflammatory chemokine interleukin (IL)-8 may promote migration of MSCs to injured sites ([@bib11], [@bib9]) and also stimulates them to secrete regenerative factors like vascular endothelial growth factor (VEGF) ([@bib64]). Detailed knowledge of the molecular events facilitating MSC homing immediately presents a variety of strategies for optimizing the process for therapeutic purposes.

Improving MSC Homing {#sec3}
====================

One of the biggest challenges facing MSC therapies is improving their homing efficiency. The percentage of intravenously (i.v.) administered MSCs that reach the target tissue is in the low single digits, as demonstrated by various imaging studies ([@bib39], [@bib8], [@bib85]). What causes this low homing efficiency? At least part of the reason is physiological: i.v.-administered MSCs get trapped in the lung capillaries ([@bib127]). Indeed, vasodilators and anticoagulants like heparin reduce lung trapping and increase MSC homing to other sites like the liver and bone marrow ([@bib55], [@bib168]). The process of homing, however, is fundamentally based on specific molecular interactions, not passive dissemination. It may be the case that the expression of homing molecules, like CXCR4, is just too low on MSCs ([@bib162], [@bib152]). It has also been observed that the *in vitro* expansion of MSCs gradually leads to the loss in expression of homing molecules ([@bib63], [@bib119]). To remedy these problems, a variety of approaches have been taken to improve MSC homing ([Figure 2](#fig2){ref-type="fig"}). These strategies can be broadly categorized into seven approaches: (1) targeted administration, (2) magnetic guidance, (3) genetic modification, (4) cell surface engineering, (5) *in vitro* priming, and (6) modification of the target tissue, and (7) radiotherapeutic techniques ([Table 1](#tbl1){ref-type="table"}).Figure 2Strategies for improving Mesenchymal Stromal Cell HomingOverview of the various strategies that have been employed to improve mesenchymal stromal cell (MSC) homing, organized by which step it targets. Arrows indicate upregulation.Table 1Overview of Strategies Targeting Each Step of Mesenchymal Stromal Cell HomingTechniqueTethering/RollingActivationArrestTransmigrationMigrationMagnetic guidance([@bib169])([@bib4], [@bib83], [@bib165], [@bib169])**Genetic modification** Infection([@bib100])([@bib28], [@bib171], [@bib12], [@bib26], [@bib57], [@bib133])([@bib88], [@bib37]) Transfection([@bib92], [@bib96], [@bib43], [@bib31])([@bib121], [@bib158])**Cell surface engineering** Enzymatic modification([@bib123], [@bib1], [@bib100], [@bib43], [@bib31]) Ligand conjugation([@bib124], [@bib27], [@bib99])([@bib161])([@bib81], [@bib82])([@bib91], [@bib60])**Priming** Culture media additives([@bib35])([@bib135], [@bib95], [@bib42], [@bib46], [@bib79], [@bib150], [@bib151], [@bib107], [@bib2], [@bib66], [@bib98], [@bib103], [@bib32], [@bib116], [@bib115])([@bib79], [@bib116], [@bib150], [@bib167], [@bib107], [@bib2], [@bib75], [@bib24]) Culture confluence([@bib78])([@bib38]) Coculture([@bib172], [@bib117])([@bib101])([@bib173])**Modification of target tissue** Direct injection([@bib164], [@bib125], [@bib126], [@bib131], [@bib130]) Genetic modification([@bib52], [@bib143], [@bib112], [@bib33]) Scaffolds([@bib80], [@bib61], [@bib58], [@bib134], [@bib128], [@bib149]) Radiotherapy([@bib114]) Ultrasound([@bib154])([@bib93], [@bib18], [@bib19], [@bib16], [@bib15], [@bib146], [@bib147], [@bib174], [@bib71], [@bib84], [@bib154])([@bib18], [@bib19], [@bib16], [@bib146], [@bib147], [@bib174], [@bib154])([@bib84])([@bib146], [@bib16])

Targeted Administration {#sec4}
=======================

Perhaps the most conceptually simple method to improve MSC homing is a physiological one: administer the cells at or near the target tissue, instead of infusing them through standard i.v. routes---that is, utilizing non-systemic rather than systemic homing. It may seem intuitive that direct delivery of MSCs to a tissue may result in greater retention, for example, intramyocardial for heart disease, intratracheal (IT) for lung disease, or intracerebral for neurological diseases.

Considerable work has gone into developing the medical technology needed for targeted administration. Indeed, several clinical trials investigating MSC therapies for ischemic cardiomyopathy use transcatheter injections directly to the myocardium ([@bib160], [@bib62]), although none have directly compared the efficacy of different routes of administration. Dick et al. took targeted delivery to the extreme by using magnetic resonance fluoroscopy to identify infarct borders real time in a porcine model ([@bib40]). Here, the authors safely navigated catheters to the infarcted region to deliver MSCs at this site. The injected MSCs were then visible upon delivery and still detectable postmortem using magnetic resonance imaging. Although this study confirmed the successful physical delivery of cells, no attempt was made to quantify the engraftment efficiency, the percentage of MSCs retained in the tissue.

Nevertheless, there is decent evidence that the route of administration has a significant effect on treatment efficacy, presumably due to increased homing. Unfortunately, although many studies administer MSCs directly to the tissue of interest, very few internally compare the targeted administration against standard i.v. administration, so the evidence for the optimal route of administration largely comes from meta-analyses. In ischemic stroke, intracerebral administration of MSCs seems to result in the best improvements in the neurological severity score, followed by intra-arterial, and then i.v. routes ([@bib153]). For myocardial infarction in swine models, transendocardial administration of MSCs seems to reduce infarct size, whereas intramyocardial, intracoronary, and i.v. administration showed no significant improvement ([@bib74]). However, in a different meta-analysis of human trials, MSCs were found to improve left ventricular ejection fraction via intracoronary, i.v., and intramyocardial routes, in descending order of effect size ([@bib72]). For bronchopulmonary dysplasia, the most effective routes of administration are, from best to worst, i.v., IT, intraperitoneal, and intranasal, with the last showing no significant improvement ([@bib6]). In acute lung injury, IT and i.v. administration both seem effective, whereas intraperitoneal is not ([@bib102]). However, the route of administration does not appear to affect MSC therapy outcomes for traumatic brain injury ([@bib111]). Evidently, it should not always be presumed that direct administration of MSCs to the target organ will yield the best outcomes. In one of the few studies that internally compared different administration routes, Antunes et al. administered MSCs into a porcine model of emphysema via either the i.v. or IT route ([@bib3]). Both routes led to decreased lung inflammation and cell damage and restored elastic fiber content. However, only the i.v. route improved cardiovascular function and shifted lung macrophage phenotypes from M1 to M2. This may be a special case for the lung, given that i.v.-administered MSCs will naturally get trapped in the lung capillaries.

Several groups have explored transplantation of MSC sheets rather than suspensions. MSC sheets are monolayers of cells that are grown in culture that then spontaneously detach with a decrease in temperature. Using a rat model of chronic myocardial infarction, Ishikane et al. transplanted MSC sheets directly onto scarred myocardium ([@bib69]). Compared with untreated controls, the treated mice showed significantly improved cardiac function, reduced myocardial fibrosis, and greater capillary density in the infarcted region. The transplantation also elicited an M2 macrophage response. Kawamura et al. showed a similar result using a xenotransplantation model of human MSC sheets into a porcine model of ischemic cardiomyopathy ([@bib76]), demonstrating improved cardiac performance, attenuated ventricular remodeling, and increased vascularization in pigs transplanted with MSC sheets, compared with controls. Unlike these previous two studies, which did not compare MSC sheet transplant against intraorgan injection, Tano et al. directly assessed the efficacy of epicardial MSC sheet placement versus intramyocardial injection in a rat model of ischemic cardiomyopathy ([@bib145]), showing that the MSC sheets improved myocardial repair more so than MSC suspensions injected intramyocardially. Using a rat model of colitis, Pak et al. endoscopically transplanted MSC sheets into the colon ([@bib110]). The MSC sheets successfully attached to the inflamed mucosa and led to significantly reduced ulcer size and inflammation compared with sham-treated controls, although no comparisons were made to other routes of administration. Kaibuchi et al. tested MSC sheet transplantation as a treatment for osteonecrosis of the jaw ([@bib73]). The MSC sheet group showed significantly improved wound healing (12.5% occurrence of bone exposure) compared with both the control and the i.v. injection groups (80% and 100% occurrence of bone exposure, respectively). The directly transplanted sheets also resulted in greater vascularization (106 vessels/mm^2^) compared with both the control and i.v. injection groups (40 and 62 vessels/mm^2^, respectively). MSC sheet transplantation may be superior to injection of MSC suspensions because of (1) a better safety profile (no risk of embolism), (2) improved donor cell survival, and (3) improved secretion of regenerative factors. Although such studies strongly indicate the importance of targeted administration, the results are of course highly dependent on the tissue and disease model.

Magnetic Guidance {#sec5}
=================

Another physical approach to targeting MSCs comes in the form of magnetic guidance, wherein cells labeled with magnetic particles are directed to the organ of interest using an external magnetic field. Arbab et al. labeled MSCs with iron oxide (ferumoxide) particles, which were injected i.v. into rats with or without an external magnet positioned over the liver ([@bib4]). Rats that wore the external magnet had around 2-fold the number of labeled MSCs in the liver 15 days post-administration. In the rats not wearing magnets, the MSCs mostly localized around the portal triad, but in the rats that did wear magnets, the MSCs infiltrated deeper into the liver parenchyma. This study did not explore which particular step of homing was enhanced, but it is presumed that the slowed intravascular movement of the MSCs played an essential role. Using an *ex vivo* system, Kobayashi et al. were able to target magnetically labeled MSCs onto an osteochondral defect in the knee joint, with the use of an external magnetic field ([@bib83]). Using an *in vivo* rat model, Yanai et al. were able to target magnetically labeled MSCs to the retina following both intravitreal or i.v. administration, with the assistance of an external magnet placed in the orbit of the rat ([@bib165]). The rats with the external magnet had significantly higher retinal levels of anti-inflammatory molecules (IL-10) and growth factors (hepatocyte growth factor \[HGF\]) compared with those without the magnet, suggesting a therapeutic benefit as well. Yun et al. successfully targeted magnetically labeled MSCs to damaged olfactory bulbs using a magnet implanted in the scalp ([@bib169]). Interestingly, they noted an upregulation of CXCR4 resulting from internalization of the magnetic particles, which would facilitate MSC activation. Much work has been done exploring different types of magnetic particles, which have varying effects on MSC viability, proliferation, differentiation, and gene expression ([@bib156]). In most studies, however, there has been no observed effect of magnetic labeling on MSC function ([@bib65], [@bib138]). Of course, in a real clinical setting, the placement of a permanent magnet must also be practical and not excessively invasive, limiting the target sites for which this technique might be useful.

Genetic Modification {#sec6}
====================

Permanent Overexpression {#sec6.1}
------------------------

Many early studies exploring genetic modification of MSCs utilized the permanent overexpression of homing factors via viral transduction. The overexpression of CXCR4 in MSCs increases their activation and engraftment to ischemic myocardium in rats, which expresses the CXCR4 ligand SDF-1. This enhanced homing has been shown to improve post-myocardial infarction recovery ([@bib28], [@bib171]). CXCR4-overexpressing MSCs also show increased homing to the bone marrow in mice ([@bib12], [@bib25]), as well as to damaged intestinal mucosa in a mouse model of colitis ([@bib26]). CXCR7 overexpression has been demonstrated to promote MSC homing to injured lung tissue ([@bib133]). However, it seems that neither CXCR4 nor CXCR7 overexpression improves homing to the kidney in mouse models of acute kidney injury (AKI) ([@bib57]).

At the step of cell arrest, overexpression of the α4-integrin, a component of the VLA-4 integrin, increases MSC homing to the bone marrow ([@bib88]). However, α4-integrin overexpression did not increase homing to the heart in a rat model of stroke, although it did decrease the formation of potentially harmful cell aggregates ([@bib37]). As with any type of gene therapy, such approaches come with inherent safety concerns; the integration of viral DNA within a tumor suppressor gene, for example, can result in insertional oncogenesis. Viral transduction is also a lengthy and relatively costly process.

Transient Overexpression {#sec6.2}
------------------------

Owing to the potential safety concerns of viral transduction, several groups have instead opted for mRNA transfection because of its simplicity, rapid protein expression, and transience. Levy et al. sought to improve MSC tethering by transfecting mRNA for PSGL-1 and SLeX, the ligands for P- and E-/L-selectin, respectively ([@bib92]). Transfected cells successfully rolled on inflamed endothelium *in vitro* and *in vivo* and showed enhanced homing to the bone marrow and the inflamed ear in a mouse model. Liao et al. used a similar transfection strategy, showing that the modified MSCs significantly increased rolling and adherence on inflamed brain microvascular endothelial cells and enhanced homing to inflamed spinal cord in a mouse model of encephalomyelitis, where they were better able to increase myelination and decrease inflammation ([@bib96]). Ryser et al. transfected CXCR4 mRNA into MSCs, which increased migration in transwell migration experiments toward an SDF-1 gradient ([@bib121]). However, Wiehe et al. were unable to replicate such results; although they successfully overexpressed CXCR4 following mRNA nucleofection, the modified MSCs showed no improvement in cell migration ([@bib158]). The authors use their results to emphasize the importance of other factors responsible for MSC activation, outside of the SDF-1/CXCR4 axis.

Cell Surface Engineering {#sec7}
========================

Enzymatic Modification {#sec7.1}
----------------------

Given the potential safety concerns of genetic modification, many groups have attempted to directly chemically engineer the cell surface of MSCs. Unlike viral transduction, these modifications are temporary. However, as transmigration occurs just a few hours post-administration ([@bib148]), even a transient modification should be sufficient to improve homing. MSCs naturally express the selectin ligand CD44, but not HCELL, the ligand for E- and L-selectin that hematopoietic stem cells use to home to the bone marrow. In a seminal study, Sackstein et al. were able to enzymatically convert CD44 into HCELL via sugar modifications (specifically, an α(1,3)-exofucosylation), allowing MSCs to utilize E- and L-selectin to tether and home to the bone marrow ([@bib148]). In a mouse model of diabetes, this modification increased infiltration of MSCs to pancreatic islets by 3-fold following i.v. administration and durably reversed hyperglycemia ([@bib1]). These sugar modifications can also be exploited via genetic modification: expression of the α(1,3)-fucosyltransferase FUT6 or FUT7 in MSCs converts CD44 to HCELL, allowing for E-selectin binding ([@bib100], [@bib43], [@bib31]).

Ligand Conjugation {#sec7.2}
------------------

Instead of modifying existing surface glycoproteins, cell surface engineering methods can be used to directly conjugate desired ligands. Sarkar et al. developed a platform that can theoretically attach any ligand to the MSC surface. They used biotinylated lipid vesicles to coat MSCs in biotin. They then attached a streptavidin adaptor, followed by biotinylated SLeX, the active site of the P-selectin ligand PSGL-1 (although any biotinylated ligand could theoretically be attached). The modification was able to improve adhesion to a P-selectin-coated surface ([@bib124]).

Cheng et al. conjugated an E-selectin-binding peptide to MSCs via an NHS-PEG~2~-maleimide linker molecule ([@bib27]). The preparation time was quick (30 min), and the modified MSCs adhered better than controls to an *in vitro* model of inflamed endothelium.

The attachment of antibodies to the MSC cell surface is another popular strategy. One such technique uses palmitated protein G: the palmityl group serves as an anchor to the cell membrane, whereas protein G serves as a dock for binding antibodies. Lo et al. used this method to attach a fragment of PSGL-1 bound to an IgG tail, which successfully facilitated tethering and rolling at high shear stresses ([@bib99]). Ko et al. used the same system to attach anti-ICAM-1 antibodies, which facilitated cell arrest in a flow chamber ([@bib81]). The same group also attached anti-VCAM-1 antibodies to MSCs, which they tested in a mouse model of inflammatory bowel disease. Compared with untreated MSCs, the anti-VCAM-1-coated MSCs showed improved homing to the inflamed lymph nodes (1.3-fold) and colon (1.8-fold), as well as dramatically improved survival rates and clinical endpoints ([@bib82]).

Bispecific antibodies have also been investigated, with one end recognizing a native MSC marker and the other end recognizing a target. Lee et al. generated bispecific antibodies, one end of which attached to CD44 on the MSC surface and the other end of which recognized myosin light chain expressed by infarcted myocardium. The armed MSCs were able to localize to the infarcted region of the heart ([@bib91]). Gundlach et al. synthesized a bispecific antibody that recognized CD90 expressed by MSCs on one end and MLC expressed by ischemic myocardium on the other end ([@bib60]). The construct improved MSC adhesion to immobilized MLC *in vitro*, although it still has not been tested *in vivo*. Both these studies seeked to enhance the migration of MSCs to the damaged tissue following extravasation by targeting injury markers at the final destination.

Unlike the previous studies that focused on the initial tethering, Won et al. sought to optimize the activation step. They conjugated recombinant CXCR4 to DMPE-PEG, a phospholipid that provides cell membrane anchoring. These modified MSCs were better able to migrate toward an SDF-1 gradient, in a CXCR4-dose-dependent manner ([@bib161]).

In nearly all these studies, cell viability, proliferation, adhesion, and differentiation were not affected. However, these cell surface engineering methods tend to be complex, requiring complicated reactions and optimization for each specific ligand or receptor.

*In Vitro* Priming {#sec8}
==================

Priming methods avoid genetic and chemical modifications entirely by simply altering culture conditions to affect gene expression. These methods have been used to improve the tethering, activation, and transmigration steps of systemic homing.

Culture Media Supplementation {#sec8.1}
-----------------------------

At the tethering step, coating MSCs with hyaluronic acid leads to the upregulation of CD44, the selectin ligand. This treatment doubled *in vitro* invasion and increased targeting to an LPS-induced inflamed ear murine model, subsequently reducing inflammation ([@bib35]).

The greatest amount of attention has been focused at the activation step by increasing CXCR4 expression. Several combinations of soluble factors have been found to increase its expression, including (1) a combination of FLT3LG, stem cell factor (SCF), IL-3, IL-6, and HGF ([@bib135]); (2) IGF-1 ([@bib95]); (3) interferon (IFN)-γ ([@bib42]); (4) IL-1β ([@bib46]); (5) glycogen synthase kinase (GSK)-3β inhibitors ([@bib79]); (6) the mood stabilizer drug valproic acid ([@bib150], [@bib151]); and (7) the iron chelator deferoxamine ([@bib107]). Hypoxic cell culture conditions induce hypoxia-inducible factor (HIF)-1α, which increases the expression of CXCR4 ([@bib2]) as well as CX3CR1 ([@bib66]) and CXCR7 ([@bib98], [@bib103]). Deferoxamine seems to stabilize HIF-1α even under normal oxygen levels ([@bib32]), increasing the expression of various homing genes ([@bib107]). Exposure to complement 1q (C1q) enhances MSC migration toward SDF-1, partly by increasing surface expression of CXCR4 ([@bib116]). Other homing receptors can be upregulated by culture conditions as well. Treatment with TNF-α was found to increase MSC migration toward chemokines by upregulating expression of several chemokine receptors including CCR2, CCR3, and CCR4, but not CXCR4 ([@bib115]).

Several of these treatments also facilitate transmigration by increasing the expression of MMPs. GSK-3β inhibitors increase MMP2 and MT1-MMP expression ([@bib79]). C1q treatment increases secretion of MMP2 ([@bib116]). Two mood stabilizer drugs, valproic acid and lithium, increase MMP2 and MMP9 activity, respectively ([@bib150]). The combination of erythropoietin and granulocyte colony-stimulating factor also increases MMP2 expression, improving MSC migration ([@bib167]). The iron chelator deferoxamine increases expression of MMP2 and MMP9 through HIF-1α signaling ([@bib107]). Hypoxic conditions seem to have a mixed effect on MMP expression: MMP2 is downregulated, whereas MT1-MMP is upregulated, although the overall effect is still significantly increased transmigration ([@bib2]). Treatment with sphingosine-1-phosphate has been found to enhance MSC migration in *in vitro* transwell assays ([@bib75]) and increase homing to infarcted myocardium, possibly by upregulating MMP9 ([@bib24]).

Culture Confluence {#sec8.2}
------------------

Interestingly, the cell culture confluence also seems to affect MSC migratory ability, although there are conflicting results in the literature. De Becker et al. found that MSCs cultured to high confluence secrete more TIMP3, an inhibitor of MMPs, resulting in decreased migration compared with MSCs cultured at low confluence ([@bib38]). Kim et al. conducted thorough gene expression profiling of MSCs grown at low or high density. Low-confluence MSCs expressed more proliferation-related genes, whereas high-confluence MSCs expressed more genes linked to activation (CXCL1, CXCL2, CXCL5, CXCL6, CXCL8, CXCL16), immune modulation (IL-1B, IL-6), migration, and regeneration (VEGFA, FGF9, PDFGD, A2M, MDK, WISP2, GDF15) ([@bib78]). Thus it is unclear whether low- or high-density MSC cultures are preferable for therapeutic applications.

Coculture {#sec8.3}
---------

Coculture with other cell populations also influences MSC migration. Sertoli cells are found in the testes and are generally thought of as "nurse cells" to developing germ cells. Coculturing MSCs with Sertoli cells upregulates proliferation genes as well as homing genes in the former, including CXCR4 ([@bib172]) and MMP-2 ([@bib101]). Coculture of amniotic MSCs with amniotic epithelial cells enhances proliferation and upregulates CXCR4 ([@bib117]). Treating MSCs with conditioned media from endothelial cells increases their migration *in vitro*, possibly due to the presence of cytokines like IL-6 and IL-8 ([@bib173]).

Modification of Target Tissue {#sec9}
=============================

All previous methods have sought to modify the MSCs to potentiate their homing ability. Instead of modifying the MSCs, however, perhaps the target tissue can be modified to make them a more attractive destination.

Direct Injection of Homing Factors {#sec9.1}
----------------------------------

The direct injection of SDF-1 into ischemic tissue has been demonstrated to enhance neovascularization in both skeletal muscle ([@bib164]) and myocardium ([@bib125], [@bib126]). Although the study did not use MSCs, Yamaguchi et al. found that SDF-1 injection into ischemic hindlimb muscle improved the homing of i.v.-infused endothelial progenitor cells 1.8-fold in mice ([@bib164]). Sasaki et al. directly injected SDF-1 into ischemic myocardium and observed increased endogenous homing of bone marrow cells, although these were not confirmed to be MSCs ([@bib125]). One critical drawback to this technique is the short half-life of SDF-1 because of its quick degradation by proteolytic enzymes. To overcome this, Segers et al. bioengineered a protease-resistant version of SDF-1 that was still capable of binding CXCR4, improve cardiac function following myocardial infarction, and improve blood flow following peripheral artery disease ([@bib131], [@bib130]). To our knowledge, no study has combined direct SDF-1 injection with MSC administration.

Genetic Modification of Target Tissue {#sec9.2}
-------------------------------------

Other groups have attempted to actually transfect the target tissue with constructs encoding for chemokines ([@bib113]). Fujii et al. used a method known as ultrasound-mediated microbubble destruction (UMMD) to deliver an SDF-1- or SCF-containing plasmid into the myocardium. The plasmids are injected alongside microbubbles, which cavitate in response to ultrasound and create shear stress that facilitates uptake of the plasmid. This technique successfully increased SDF-1 expression in the myocardium and increased homing of endogenous CXCR4-expressing progenitor cells ([@bib52]). Sundararaman et al. achieved similar results without the use of UMMD, instead injecting the SDF-1 plasmid directly into the heart ([@bib143]). Treated mice showed improved angiogenesis and cardiac function. This therapy was taken into a phase I clinical trial, where 17 patients with ischemic cardiomyopathy were administered the SDF-1 plasmid directly do the infarcted region ([@bib112]). After 12 months, the patients demonstrated improvements in walk distance and quality of life, in a dose-dependent manner. This initial human study did not include a control group. In the follow-up phase II placebo-controlled study, there was no significant difference between placebo and treatment groups based on the primary endpoints of 6-min walk distance or the Minnesota Living with Heart Failure Questionnaire score ([@bib33]). However, by limiting the analysis to the sickest one-third of patients, there was significant improvement in ejection fraction, attenuation of left ventricle size, and stroke volume. As is the case with the genetic modification of MSCs, though, transfection of the target tissue comes with concerns regarding immunogenicity and insertional mutagenesis, as well as cost.

Scaffold Implantation {#sec9.3}
---------------------

A final method of cytokine delivery comes in the form of scaffolds. Many of the scaffolds being studied release SDF-1 after they are implanted at the target site. Kimura and Tabata developed a gelatin hydrogel that slowly releases SDF-1. Subcutaneous implantation of the hydrogel was superior to injection of SDF-1, as measured by angiogenesis and CXCR4 expression at the implantation site ([@bib80]). Similarly, He et al. synthesized a poly(lactide ethylene oxide fumarate) hydrogel loaded with SDF-1, which was able to increase bone marrow stromal cell migration *in vitro* in a dose-dependent manner ([@bib61]). Goncalves et al. developed a chitosan/poly(γ-glutamic acid) complex incorporated with SDF-1, which increased MSC migration *in vitro* ([@bib58]). Shen et al. engineered a bioactive knitted silk-collagen sponge scaffold that could be incorporated with SDF-1. In a rat Achilles tendon injury model, the scaffold successfully enhanced migration of endogenous progenitor cells and enhanced tendon regeneration ([@bib134]). In a slightly more involved system, Schantz et al. developed a cellular polycaprolactone scaffold, from which SDF-1 could be constantly delivered using a microneedle apparatus ([@bib128]). Similarly, Thevenot et al. designed a poly(lactic-co-glycolic acid) scaffold that releases SDF-1 via a miniosmotic pump. After subcutaneous implant in mice, these scaffolds resulted in a 3-fold increase in homing ([@bib149]). Although such scaffolds may serve as a "homing beacon" for MSCs, they may be difficult to optimize, and come with safety and cost concerns.

Radiotherapeutic Techniques {#sec9.4}
---------------------------

When target tissues are irradiated, they show a higher rate of MSC engraftment ([@bib23], [@bib105]). This increase is due to upregulated expression of SDF-1, thus promoting the activation step of homing ([@bib114]). Of course, radiation therapy comes with inherent safety concerns in human patients, and so although these results are conceptually interesting, it may not be an option that can be implemented clinically. This is especially true with safer alternative techniques that achieve similar improvements in MSC homing---namely, the use of sound waves.

Ultrasound Techniques {#sec9.5}
---------------------

In addition to its diagnostic applications, ultrasound has been adopted for a variety of therapeutic applications ([@bib104]). Unlike diagnostic ultrasound, therapeutic ultrasound is selectively focused on the tissue of interest. Sophisticated image guidance technology allows for the targeting of deep structures without affecting intervening tissue. At the target site, the mechanical pressure exerted by sound waves induces various biological effects that aid in regeneration.

Many studies have investigated UMMD for improving MSC homing. In this technique, microbubbles are administered systemically alongside the MSCs. Ultrasound is focused on the target tissue, which cavitates the microbubbles, causing shock waves and shear stress that exert various biological effects. These effects include changes in gene expression, and the disruption of endothelial linings, which increases vascular permeability. Several studies have utilized UMMD in combination with MSCs to increase cardiac recovery following myocardial infarction ([@bib170], [@bib56], [@bib163]). This effect likely arises from both the increased vascular permeability, as well as changes in gene expression. Li et al. found that UMMD both elevates secretion of SDF-1 on the target tissue and increases the proportion of MSCs that express CXCR4 ([@bib93]). In the kidney, UMMD has been shown to promote MSC homing by the upregulation of cytokines, integrins, selectins, and other trophic factors ([@bib154]). UMMD to the brain has been shown to induce a sterile inflammatory response that upregulates a variety of inflammatory and trophic factors, including MMPs ([@bib84]), although MSC homing has not yet been assessed in this system. However, as microbubble cavitation is known to be damaging to the host tissue ([@bib14], [@bib30], [@bib45]), some investigators have begun looking into focused ultrasound without microbubbles.

Pulsed focused ultrasound (pFUS), as its name implies, administers focused pulses of high-intensity sound waves. The non-continuous administration of the waves prevents extreme temperatures and tissue damage ([@bib19]). Instead, pFUS exerts its effects solely by mechanical pressure, activating mechanotransduction pathways that upregulate inflammatory and chemoattractive molecules ([@bib174]). There has been a quickly growing body of literature studying the molecular changes induced by pFUS. In the muscle, Burks et al. demonstrated that pFUS creates a transient local chemical gradient. Upregulated molecules include cytokines, growth factors, and cell adhesion molecules, like ICAM-1 and VCAM-1 ([@bib18]). This chemical gradient enhances homing of MSCs to the muscle and induces an anti-inflammatory M2 macrophage response ([@bib19]). To establish this local gradient, pFUS seems to induce an initial activation of TNF-α, which drives cyclooxygenase-2 (COX2) signaling that upregulates various cytokines and homing factors ([@bib146]). In a mouse model of limb ischemia, pFUS + MSCs increased MSC homing 4-fold compared with MSCs alone, resulting in improved clinical outcomes ([@bib147]). Parallel results have been achieved in the kidney, where pFUS created a similar chemical gradient without any physiological damage to the host tissue, and dramatically increased MSC homing ([@bib174]). Similar to muscle, pFUS causes initial activation of TNFα and IL-1α in the kidney, which drive signaling through the nuclear factor-κB and COX2 pathways ([@bib16]). In a mouse model of cisplatin-induced AKI, pFUS + MSCs significantly enhanced kidney homing and clinical outcomes compared with MSCs alone ([@bib17]). In the AKI model, pFUS was found to upregulate IFN-γ in the kidney, which signals MSCs to produce the anti-inflammatory IL-10 ([@bib15]). Jang et al. used pFUS on the heart and observed a similar initial increase in TNF-α followed by the upregulation of cytokines and growth factors, although MSC homing was not assessed ([@bib71]). Although further studies are needed on its long-term effects, ultrasound appears to be a promising avenue for enhancing MSC homing.

Conclusions {#sec9.6}
-----------

The effort to improve MSC homing has taken on a wide breadth of strategies. Some of these strategies focus on non-systemic homing, such as the targeted administration and magnetic guidance. Most of the other techniques discussed here focus on systemic homing, a multistep process governed by specific molecular interactions. Unlike our relatively comprehensive knowledge on the homing of blood cells ([@bib106]), MSC homing mechanisms remain poorly understood at several steps, such as tethering or rolling and transmigration. It is also unclear which of these steps is the major bottleneck for MSC attrition and would thus be the most fruitful for further investigation. Understanding the underlying biology has provided a wealth of optimization strategies at each step of the homing process. Each approach comes with its own drawbacks. Targeted administration may not always be feasible or may be highly invasive, depending on the target tissue. Most modifications to the MSCs do not prevent them from distributing to non-targeted organs. On the other hand, modifying the target tissue via chemical or genetic means raises safety concerns. These limitations present formidable barriers to applying them in the clinic. Although still an active area of study, the use of ultrasound to enhance MSC homing seems a promising avenue, with easy targeting of both deep and superficial organs and, to our current knowledge, a lack of significant safety concerns.

Although homing is perhaps the major impediment to realizing MSC-based therapies, other hurdles lie in the way as well. MSCs used in clinical settings are derived from healthy donors, and although these cells may be homogeneous in their expression of defining surface markers, they are not necessarily homogeneous in their function. Notably, the activity of IFN-γ-induced Indoleamine 2,3-dioxygenase (IDO) has been shown to be critical for MSC-facilitated immunosuppression, but donor variation gives rise to substantial differences in IDO responsiveness ([@bib48]). Furthermore, large-scale *in vitro* expansion of MSCs, which is necessary for clinical applications, results in senescence that impairs their therapeutic effect ([@bib21]). Contrary to conventional wisdom, which states that MSCs are immune privileged, studies have shown that MSCs may in fact undergo immune rejection due to HLA mismatches ([@bib108], [@bib44]). Finally, clinical trials almost universally use freshly thawed MSC stocks; however, cryopreservation appears to impair the immunosuppressive properties of MSCs and shorten their persistence *in vivo* ([@bib47], [@bib29]). These difficulties may well be the cause of conflicting results in both basic science and clinical settings ([@bib53]). Moving forward, it will be critical to be cognizant of these sources of variation. Although much work still needs to be done, tackling the basic biological mechanisms underlying MSC biology will reveal new paths for optimization. Such investigations will continue to push forward the field of cell-based therapies, broadly boosting the effectiveness of therapeutics in applications ranging from immune modulation to regeneration.
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